Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 338

1.

Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.

Robberstad B, Frostad CR, Akselsen PE, Kværner KJ, Berstad AK.

Vaccine. 2011 Nov 3;29(47):8564-74. doi: 10.1016/j.vaccine.2011.09.025. Epub 2011 Sep 21.

PMID:
21945264
2.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006. Epub 2013 Jan 10.

PMID:
23312274
3.

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

Butler JR, McIntyre P, MacIntyre CR, Gilmour R, Howarth AL, Sander B.

Vaccine. 2004 Mar 12;22(9-10):1138-49.

PMID:
15003641
4.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.

Blank PR, Szucs TD.

Vaccine. 2012 Jun 13;30(28):4267-75. doi: 10.1016/j.vaccine.2012.04.028. Epub 2012 Apr 20.

PMID:
22521287
5.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
6.

Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.

De Wals P, Black S, Borrow R, Pearce D.

Clin Ther. 2009 Oct;31(10):2152-69. doi: 10.1016/j.clinthera.2009.10.014.

PMID:
19922887
7.

Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.

Gomez JA, Tirado JC, Navarro Rojas AA, Castrejon Alba MM, Topachevskyi O.

BMC Public Health. 2013 Oct 30;13:1025. doi: 10.1186/1471-2458-13-1025.

8.

Comparing health outcomes and costs of general vaccination with pneumococcal conjugate vaccines in Sweden: a Markov model.

By A, Sobocki P, Forsgren A, Silfverdal SA.

Clin Ther. 2012 Jan;34(1):177-89. doi: 10.1016/j.clinthera.2011.12.007.

PMID:
22284997
9.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
10.

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries.

Talbird SE, Taylor TN, Knoll S, Frostad CR, García Martí S.

Vaccine. 2010 Nov 19;28 Suppl 6:G23-9. doi: 10.1016/j.vaccine.2010.06.016.

PMID:
21075266
11.

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands.

Strutton DR, Farkouh RA, Earnshaw SR, Hwang S, Theidel U, Kontodimas S, Klok R, Papanicolaou S.

J Infect. 2012 Jan;64(1):54-67. doi: 10.1016/j.jinf.2011.10.015. Epub 2011 Nov 4.

PMID:
22085813
12.

New vaccines against otitis media: projected benefits and cost-effectiveness.

O'Brien MA, Prosser LA, Paradise JL, Ray GT, Kulldorff M, Kurs-Lasky M, Hinrichsen VL, Mehta J, Colborn DK, Lieu TA.

Pediatrics. 2009 Jun;123(6):1452-63. doi: 10.1542/peds.2008-1482.

PMID:
19482754
13.

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada.

Earnshaw SR, McDade CL, Zanotti G, Farkouh RA, Strutton D.

BMC Infect Dis. 2012 Apr 24;12:101. doi: 10.1186/1471-2334-12-101.

14.

Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.

Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK.

JAMA. 2012 Feb 22;307(8):804-12. doi: 10.1001/jama.2012.169.

15.

Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.

Boonacker CW, Broos PH, Sanders EA, Schilder AG, Rovers MM.

Pharmacoeconomics. 2011 Mar;29(3):199-211. doi: 10.2165/11584930-000000000-00000. Review.

PMID:
21250759
16.

The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.

Silfverdal SA, Berg S, Hemlin C, Jokinen I.

Vaccine. 2009 Mar 4;27(10):1601-8. doi: 10.1016/j.vaccine.2008.12.033. Epub 2009 Jan 13.

PMID:
19146905
17.

Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise.

Knerer G, Ismaila A, Pearce D.

J Med Econ. 2012;15(1):61-76. doi: 10.3111/13696998.2011.622323. Epub 2011 Oct 25.

PMID:
22026590
18.

Modelling the effect of conjugate vaccines in pneumococcal disease: cohort or population models?

Standaert B, Demarteau N, Talbird S, Mauskopf J.

Vaccine. 2010 Nov 19;28 Suppl 6:G30-8. doi: 10.1016/j.vaccine.2010.06.015.

PMID:
21075268
19.

Cost-effectiveness of new adult pneumococcal vaccination strategies in Italy.

Boccalini S, Bechini A, Levi M, Tiscione E, Gasparini R, Bonanni P.

Hum Vaccin Immunother. 2013 Mar;9(3):699-706. Epub 2013 Jan 7.

20.

Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong.

Lee KK, Rinaldi F, Chan MK, Chan ST, So TM, Hon EK, Lee VW.

Value Health. 2009 Nov-Dec;12 Suppl 3:S42-8. doi: 10.1111/j.1524-4733.2009.00626.x.

Items per page

Supplemental Content

Write to the Help Desk